Vildagliptin enhances differentiation of insulin producing cells from adipose-derived mesenchymal stem cells

ABSTRACT

Objective: Type 1 diabetes is caused by destruction of beta cells of pancreas. Vildagliptin [VG], a dipeptidyl peptidase IV [DPP IV] inhibitor, is an anti-diabetic drug, which increases beta cell mass. In the present study, the effects of VG on generation of insulin-producing cells [IPCs] from adipose-derived mesenchymal stem cells [ASCs] is investigated